Skip to main content

ESTRATEGIAS PARA SILENCIAR LA COMUNICACION ENTRE LOS FIBROBLASTOS-ASOCIADOS A CANCER Y EL MICROAMBIENTE TUMORAL EN CANCER COLORECTAL

PID2021-128107OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2021
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Lockpicking FGFR1 with aptamer-based technology

  • Nonatelli, Francesca
  • Pastor, Fernando
  • Calvo, Fernando
Targeting undruggable proteins and achieving high selectivity remain critical challenges in molecular therapeutics, as the lack of well-defined binding pockets, along with off-target effects leading to toxicity and reduced efficacy, often hampers drug development. The study by Zlinska et al.1 leverages aptamer technology to develop new molecular and therapeutic tools for fibroblast growth factor receptor-1 (FGFR1) modulation. It describes a novel DNA G-quadruplex aptamer (called VZ23), which specifically binds to FGFR1 without affecting other FGFR variants, effectively inhibiting FGFR1 signaling and its cellular responses (Figure 1). This finding offers new potential solutions for treating several pathologies where FGFR1 is relevant, including cancer, skeletal and developmental disorders, and metabolic syndromes., This work was supported by grants to F.C. from the Spanish Government MICIU/AEI/10.13039/501100011033 (PID2021-128107OB-I00); Asociación Española Contra el Cáncer-AECC (PRYCO211372RODR), and the European Research Council-ERC Consolidator Grant antiCAFing (grant no. 101045756). F.P. is supported by Instituto de Salud Carlos III y Fondos Feder (PI23/01120), Estratégicos Asociación Española Contra el Cáncer (AECC PRYES235096PAST), H2020-FETOPEN “DESTINATION” (grant no. 899833), and Gobierno de Navarra Estratégicos “REVOLUTION” (0011-1411-2024-000110)., Peer reviewed